CRL 1605
Latest Information Update: 29 Sep 2022
At a glance
- Originator CytRx Corporation
- Developer LadRx Corporation
- Class Antibacterials; Antineoplastics
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 28 Dec 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 04 Mar 1999 New profile